Fennec Pharmaceuticals Inc (FENC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has a cash flow conversion efficiency ratio of 0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.38 Million) by net assets ($37.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FENC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Fennec Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Fennec Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fennec Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reconnaissance Energy Africa Ltd
V:RECO
|
-0.010x |
|
Medios AG
XETRA:ILM1
|
0.021x |
|
Precious Shipping Public Company Limited
BK:PSL-R
|
0.038x |
|
Shenzhen Capol International & Associates Co Ltd
SHE:002949
|
0.064x |
|
E1 Corporation
KO:017940
|
-0.056x |
|
Jiangsu Gaoke Petrochemical Co
SHE:002778
|
0.114x |
|
United Malacca Bhd
KLSE:2593
|
0.121x |
|
Pro Real Estate Investment Trust
TO:PRV-UN
|
0.019x |
Annual Cash Flow Conversion Efficiency for Fennec Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Fennec Pharmaceuticals Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Fennec Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.05 Million | $-12.47 Million | -0.356x | +92.26% |
| 2024-12-31 | $-5.87 Million | $26.98 Million | -4.595x | -411.49% |
| 2023-12-31 | $-11.62 Million | $-17.14 Million | 1.475x | -79.02% |
| 2022-12-31 | $-2.57 Million | $-18.06 Million | 7.029x | +879.53% |
| 2021-12-31 | $15.77 Million | $-14.22 Million | -0.902x | -68.09% |
| 2020-12-31 | $29.07 Million | $-15.60 Million | -0.536x | +29.69% |
| 2019-12-31 | $11.88 Million | $-9.06 Million | -0.763x | -107.78% |
| 2018-12-31 | $21.31 Million | $-7.83 Million | -0.367x | -169.84% |
| 2017-12-31 | $26.76 Million | $-3.64 Million | -0.136x | +77.13% |
| 2016-12-31 | $3.57 Million | $-2.12 Million | -0.595x | +82.49% |
| 2015-12-31 | $548.00K | $-1.86 Million | -3.398x | -22.59% |
| 2014-12-31 | $613.00K | $-1.70 Million | -2.772x | -282.48% |
| 2013-12-31 | $-1.46 Million | $-2.21 Million | 1.519x | +151.48% |
| 2012-12-31 | $-4.96 Million | $-2.99 Million | 0.604x | -97.75% |
| 2011-12-31 | $-120.00K | $-3.23 Million | 26.883x | +6765.85% |
| 2010-12-31 | $-4.92 Million | $-1.93 Million | 0.392x | +103.39% |
| 2009-12-31 | $406.00K | $-4.69 Million | -11.547x | -226.17% |
| 2008-12-31 | $3.05 Million | $-10.81 Million | -3.540x | -276.50% |
| 2007-12-31 | $14.15 Million | $-13.30 Million | -0.940x | +47.07% |
| 2006-12-31 | $7.58 Million | $-13.47 Million | -1.777x | -190.61% |
| 2005-12-31 | $20.06 Million | $-12.26 Million | -0.611x | -236.82% |
| 2003-12-31 | $33.00 Million | $-5.99 Million | -0.181x | +48.85% |
| 2002-12-31 | $15.31 Million | $-5.43 Million | -0.355x | +33.18% |
| 2001-12-31 | $6.08 Million | $-3.23 Million | -0.531x | -93.96% |
| 2000-12-31 | $9.82 Million | $-2.69 Million | -0.274x | +98.95% |
| 1999-12-31 | $46.73K | $-1.22 Million | -26.189x | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more